Trials / Completed
CompletedNCT02939391
A Study of KW-6356 in Subjects With Early Parkinson's Disease
An Early Phase 2 Study of KW-6356 in Subject With Early Parkinson's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 175 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to evaluate the effect of KW-6356 on motor symptoms in Parkinson's disease and the primary endpoint is the change from baseline in the MDS-UPDRS part III score between KW-6356 and placebo in subjects with early Parkinson's disease in Japan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KW-6356 | Oral administration |
| DRUG | KW-6356 | Oral administration |
| DRUG | Placebo | Oral administration |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2017-11-22
- Completion
- 2017-12-08
- First posted
- 2016-10-20
- Last updated
- 2018-03-20
Locations
7 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02939391. Inclusion in this directory is not an endorsement.